Balyasny Asset Management
AMLX icon

Balyasny Asset Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Balyasny Asset Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-425,000
Closed -$9.17M – 2224
2023
Q2 		$9.17M Buy
+425,000
New +$11.5M 0.02% 827

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Balyasny Asset Management's AMLX Position: Q1 2026 in Review

Balyasny Asset Management increased its Amylyx Pharmaceuticals (AMLX) stake by 29% in Q1 2026, buying an estimated $3.5M and bringing the position to 1,107,271 shares worth $15.4M. The position accounts for 0.02% of the portfolio, ranked #803.

Balyasny Asset Management first reported a position in AMLX in Q1 2022 and has held it in 14 quarters since. The position peaked at $25.3M in Q2 2023. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Balyasny Asset Management held 1,107,271 shares of Amylyx Pharmaceuticals worth $15.4M as of Q1 2026.
  • Balyasny Asset Management bought 248,587 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $3.5M.
  • Amylyx Pharmaceuticals made up 0.02% of Balyasny Asset Management's portfolio in Q1 2026, its #803 holding.
  • Balyasny Asset Management first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 14 quarters since.
  • Balyasny Asset Management's Amylyx Pharmaceuticals position peaked at $25.3M in Q2 2023.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.